Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(29 sites)
China
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui Anhui Provincial Hospital, Hefei, Anhui Peking University Third Hospital, Beijing, Beijing Municipality Beijing Chao Yang Hospital,Capital Medical University, Beijing, Beijing Municipality Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing, Chongqing Municipality